Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway

References

• Seeff LB. The history of the “natural history” of hepatitis C (1968–2009). Liver Int. 2009;29:89–99.
   PubMed Web of Science ®Google Scholar
• The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2: 161–176.
   PubMed Web of Science ®Google Scholar
• Büsch K, Waldenström J, Lagging M, et al. Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scand J Gastroenterol. 2017;52:61–68.
   PubMed Web of Science ®Google Scholar
• Dalgard O, Jeansson S, Skaug K, et al. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol. 2003;38:864–870.
   PubMed Web of Science ®Google Scholar
• Duberg A-S, Blach S, Falconer K, et al. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015;50:233–244.
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–327.
   PubMed Web of Science ®Google Scholar
• Palanisamy N, Danielsson A, Kokkula C, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013;99:12–17.
   PubMed Web of Science ®Google Scholar
• Alberti A, Lacoin L, Morais E, et al. Literature review of the distribution of hepatitis C virus genotypes across Europe. J Med Virol. 2016;88:2157–2169.
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.
   PubMed Web of Science ®Google Scholar
• Wyles DL. Resistance to DAAs: when to look and when it matters. Curr HIV/AIDS Rep. 2017;14:229–237.
   PubMed Web of Science ®Google Scholar
• Kileng H, Kjellin M, Akaberi D, et al. Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014–2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy. Scand J Gastroenterol. 2018;53:1347–1353.
   PubMed Web of Science ®Google Scholar
• Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance–associated substitutions: state of the art summary. Hepatology. 2015;62:1623–1632.
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–194.
   PubMed Web of Science ®Google Scholar
• Bergfors A, Leenheer D, Bergqvist A, et al. Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing. Antiviral Res. 2016;126:81–89.
   PubMed Web of Science ®Google Scholar
• Hernandez D, Zhou N, Ueland J, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57:13–18.
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Dvory-Sobol H, Doehle BP, et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother. 2016;AAC:00763–00716.
   Google Scholar
• Palanisamy N, Kalaghatgi P, Akaberi D, et al. Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals. Antivir Ther. 2018;23:485–493.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–1135.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Leroy V, Angus P, Bronowicki J-P, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY‐3+). Hepatology. 2016;63:1430–1441.
   PubMed Web of Science ®Google Scholar
• Esteban R, Pineda JA, Calleja JL, et al. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology. 2018;155:1120–1127.e4.
   PubMed Web of Science ®Google Scholar
• The Norwegian Medical Association. Faglig veileder for utredning og behandling av hepatitt C. 2014 [cited 2018 Jan 8]. Available from: http://legeforeningen.no/PageFiles/246436/Veileder%20sept%202014.pdf
   Google Scholar
• The Norwegian Medical Association. Faglig veileder for utredning og behandling av hepatitt C. 2015 [cited 2015; National guidelines]. Available from: http://gastroenterologen.no/filer/Veileder-Revisjon-mars-2015.pdf
   Google Scholar
• Sykehusinnkjøp HF. LIS recommondations for HCV treatment. Oslo (Norway): Sykehusinnkjøp HF; 2016.
   Google Scholar
• RAV Referensgruppen för AntiViral terapi. Antiviral treatment of hepatitis C. 2017 [cited 2017]. Available from: https://www.sls.se/rav/rekommendationer/hepatit-c-virus/
   Google Scholar
• The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20.
   PubMed Web of Science ®Google Scholar
• Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350.
   PubMed Web of Science ®Google Scholar
• Lindström I, Kjellin M, Palanisamy N, et al. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden. Infect Dis. 2015;47:555–562.
   PubMed Web of Science ®Google Scholar
• Kalaghatgi P, Sikorski AM, Knops E, et al. Geno2pheno [HCV]–a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One. 2016;11:e0155869.
   PubMed Web of Science ®Google Scholar
• Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat. 2018;37:17–39.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.
   PubMed Web of Science ®Google Scholar
• Norwegian Institute of Public Health. Usage of Antivirals and the Occurence of Antiviral resitance in Norway in 2017. 2018 [cited 2019 Jan 23]. Available from: https://www.fhi.no/en/publ/2018/usage-of-antivirals-and-the-occurrence-of-antiviral-resistance-in-norway-20/
   Google Scholar
• Belperio PS, Shahoumian TA, Loomis TP, et al. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol. 2019;70:15–23.
   PubMed Web of Science ®Google Scholar
• Howe A, Cento V, Garcia F, et al. A real world resistance profile of virologic failures collected from an international collaboration (SHARED). In: Hepatology. Hoboken (NJ): Wiley; 2018.
   Google Scholar
• Krishnan P, Pilot-Matias T, Schnell G, et al. Pooled resistance analysis in HCV genotype 1-6 infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. Antimicrob Agents Chemother. 2018;62:e01249–18.
   PubMed Web of Science ®Google Scholar
• Sykehusinnkjøp HF. LIS recommondations for HCV treatment. 2019 [cited 2019 Feb 14]. Available from: https://sykehusinnkjop.no/Documents/Legemidler/Avtaler%20og%20anbefalinger/2019/Uten%20priser%20Hepatitt%20C%20anbefalinger%202019%20og%202020.pdf
   Google Scholar